Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Alaunos Therapeutics, Inc. TCRT

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$5,000
▼ 50.0% YoY
$-4.2M
$-3.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 5,000.00
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -4.2
-100M-200M
2007201020132016201920222025
Compound annual growth
−88.0%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -84500.0% · Net ·
-50000%
200720162025
ROE
FY2025 · ROE -198.1%
-50%-100%-150%
200720162025
Three returns, three denominators.

Each USD of equity lost 198 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -3.0
-30M-60M
200720162025
Net buybacks $M Dividends $M
FY2023 · Dividends · · Net buybacks -0.1
-40M-80M
20092011201320152017201920222023

Total assetsUSD 3.0M
EquityUSD 2.2M
CashUSD 1.4M
Current ratio2.45×

Equity funds 73% of total assets.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
TCRT, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B0.00.00.00.00.00.0◌0.00.00.0◌◌◌0.00.0◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.1−0.1−0.1−0.1−0.1−0.2−0.1−0.0−0.1−0.1−0.1−0.0−0.0◌◌
EBITDA $B−0.0−0.0−0.0−0.0−0.1−0.1−0.1−0.1−0.1−0.2−0.1◌◌◌◌◌◌◌◌
Income tax $B0.0◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.1−0.1−0.1−0.1−0.1−0.2−0.1−0.0−0.1−0.1−0.1−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.1−0.1−0.0−0.0−0.1−0.1−0.0−0.0−0.1−0.1−0.0−0.0−0.0◌◌
EPS, diluted $−2.20−2.92−21.97−2.61−0.37−0.38−0.700.96−0.53−1.32−0.96−0.31−0.66−1.22−0.97−0.71−0.33◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %−198.1−111.8−20.9−78.1−86.5−73.0−130.5———−198.1−76.4−116.7−160.2−124.9−111.4−43.9−136.0−87.6
Shares out B0.000.000.020.240.220.210.180.160.140.130.130.100.100.080.070.05◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 67 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: the share count is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image